Strong Performance Yet… 18% Drop in Sleep Apnea Leader Over One Year

ResMed Inc. (NYSE: RMD), a U.S.-based sleep apnea treatment device maker, closed 6.07% lower at $191.07 on the New York Stock Exchange, erasing roughly $1.6 billion in market capitalization—about ₩2 trillion—in a single trading session. The company’s market cap now stands at approximately $27.7 billion, or around ₩37 trillion. The stock has been on a downward trend over the past year, hitting fresh 52-week lows.

According to Investing.com, ResMed’s shares touched a 52-week intraday low today and have fallen about 18% over the last year, reflecting what analysts call a “challenging year.” Despite this, the company outperformed market expectations in its fiscal 2026 third-quarter results, released at the end of April, reporting revenue of about $1.43 billion and adjusted earnings per share of $2.86. ResMed also delivered double-digit growth, expanded margins, and continued share repurchases, underscoring its solid fundamentals.

Headquartered in San Diego, ResMed is a global medical-device firm specializing in the development and production of CPAP machines, masks, and cloud-based software for treating sleep apnea and chronic obstructive pulmonary disease. The company ranks among the leaders in the global sleep apnea device market alongside Philips-affiliated competitors, with demographic aging and rising awareness of sleep disorders cited as key long-term growth drivers.